Cargando…

A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy

Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) is the current standard of treatment for choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD), but there are no diagnostic tools to predict response of these therapies. We hyp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Yan, Teo, Yi Chong Kelvin, Beuerman, Roger W., Wong, Tien Yin, Zhou, Lei, Cheung, Chui Ming Gemmy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987119/ https://www.ncbi.nlm.nih.gov/pubmed/31992792 http://dx.doi.org/10.1038/s41598-020-58346-3

Ejemplares similares

Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients
por: Skelly, Adrian, et al.
Publicado: (2019)

Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER
por: Tadayoni, Ramin, et al.
Publicado: (2023)

Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD
por: Chakravarthy, Usha, et al.
Publicado: (2021)

Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway
por: Reitan, Gudrun, et al.
Publicado: (2023)

Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study
por: Tan, Colin S., et al.
Publicado: (2020)

Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis
por: Sheth, Veeral, et al.
Publicado: (2022)

“What should I inject next?” Challenging treatment decisions in the multiple anti-VEGF: a review of publications exploring anti-VEGF switching for nAMD
por: Pikkel, Joseph, et al.
Publicado: (2017)

Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment
por: Hatamnejad, Amin, et al.
Publicado: (2023)

Communicating with patients with nAMD and their families during the COVID-19 pandemic
por: Korobelnik, Jean-François, et al.
Publicado: (2020)

Aflibercept Does Not Suppress Angiopoietin-2 in Patients With nAMD or DME
por: Avery, Robert L., et al.
Publicado: (2023)

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
por: Patel, Prem, et al.
Publicado: (2021)

A model to quantify the influence of treatment patterns and optimize outcomes in nAMD
por: Ziemssen, Focke, et al.
Publicado: (2022)

Strongest Correlation Between Contrast Sensitivity and Morphological Characteristics in Bilateral nAMD
por: Hoffmann, Laura, et al.
Publicado: (2021)

Impact of intravitreal injection therapy on contrast sensitivity in patients with nAMD and DME
por: Dieke, Sebastian, et al.
Publicado: (2023)

Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration
por: Ozdemir, Semra, et al.
Publicado: (2022)

One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
por: Coney, Joseph M, et al.
Publicado: (2023)

The Efficacy and Safety of Brolucizumab for the Treatment of nAMD: A Systematic Review and Meta-Analysis
por: Chuan, Junlan, et al.
Publicado: (2022)

Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD
por: Kamao, Hiroyuki, et al.
Publicado: (2018)

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
por: Sarkar, Aira, et al.
Publicado: (2021)

Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
por: Tan, Colin S, et al.
Publicado: (2022)

nAMD: optimization of patient care and patient-oriented information with the help of an internet-based survey
por: Schmid, Anke, et al.
Publicado: (2022)

Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence
por: Teo, Kelvin Yi Chong, et al.
Publicado: (2020)

The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis
por: Danyliv, Andriy, et al.
Publicado: (2017)

Erratum to: The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis
por: Danyliv, Andriy, et al.
Publicado: (2017)

Systemic counterregulatory response of angiopoietin‐2 after aflibercept therapy for nAMD: a potential escape mechanism
por: Angermann, Reinhard, et al.
Publicado: (2020)

Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD
por: Kiss, Szilárd, et al.
Publicado: (2020)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)

Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service
por: Gale, Richard P., et al.
Publicado: (2019)

A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
por: Johnston, Robert L., et al.
Publicado: (2017)

Contrast sensitivity and binocular reading speed best correlating with near distance vision‐related quality of life in bilateral nAMD
por: Rossouw, Petra, et al.
Publicado: (2020)

Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
por: Arruabarrena, Carolina, et al.
Publicado: (2021)

The COVID-19 Pandemic and Ophthalmic Care: A Qualitative Study of Patients with Neovascular Age-Related Macular Degeneration (nAMD)
por: O’Connor, Seán R., et al.
Publicado: (2022)

Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis
por: Tsai, Ching-Yao, et al.
Publicado: (2023)

Anti-VEGF Treatment Strategies for Wet AMD
por: Kovach, Jaclyn L., et al.
Publicado: (2012)

ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD)
por: Liakopoulos, Sandra, et al.
Publicado: (2020)

Interleukin-1β Level Is Increased in Vitreous of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Polypoidal Choroidal Vasculopathy (PCV)
por: Zhao, Min, et al.
Publicado: (2015)

Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
por: Tran, Thi Ha Chau, et al.
Publicado: (2017)

Angiogenin, FGF-α, and IL-36β have higher expression levels in aqueous humor of nAMD patients in comparison to cataract patients
por: Chen, Kailin, et al.
Publicado: (2020)

Findings of uncertain significance by optical coherence tomography (OCT) as prognostic factors in neovascular age-related macular degeneration (nAMD) treated with ranibizumab
por: Hayashi-Mercado, Ricardo, et al.
Publicado: (2022)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1obo61l43mn9isro06pap0tpll